MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
0.9303
+0.1081
+13.15%
After Hours: 0.9399 +0.0096 +1.03% 19:26 02/06 EST
OPEN
0.8585
PREV CLOSE
0.8222
HIGH
0.9468
LOW
0.8237
VOLUME
220.06K
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
0.7970
MARKET CAP
24.46M
P/E (TTM)
-0.3327
1D
5D
1M
3M
1Y
5Y
1D
Senti Biosciences to Present Gene Circuit Platform at Healthcare Conference Taipei
Reuters · 5d ago
Weekly Report: what happened at SNTI last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at SNTI last week (0119-0123)?
Weekly Report · 01/26 09:25
Weekly Report: what happened at SNTI last week (0112-0116)?
Weekly Report · 01/19 09:28
Senti Biosciences Announces New Clinical Data and RMAT Designation for SENTI-202 in AML Trial
Reuters · 01/14 14:15
Senti Biosciences CEO Highlights AML Breakthroughs and RMAT Status at Virtual Investor Event
Reuters · 01/14 14:15
Press Release: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
Dow Jones · 01/14 14:15
Weekly Report: what happened at SNTI last week (0105-0109)?
Weekly Report · 01/12 09:27
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.